Plant Name: Vincetoxicum stauntonii
Taxonomic Information:
Plant ID: NPO10366
Plant Latin Name: Vincetoxicum stauntonii
Taxonomy Genus: Vincetoxicum
Taxonomy Family: Apocynaceae
Plant External Links:
NCBI TaxonomyDB:
516547
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA2C; HRH3; ADRA2A; | |
| TSHR; | |
| TDP1; POLB; | |
| MAPK1; | |
| CA2; | |
| PPARA; | |
| TLR2; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP3A4; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | HRH3 | Histamine H3 receptor | Q9Y5N1 | CHEMBL264 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.254E-06 | 9.101E-03 | ADRA2A, ADRA2C |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 2.507E-06 | 1.010E-02 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 2.507E-06 | 1.010E-02 | ADRA2A, ADRA2C |
| BP | GO:0065007; biological regulation | GO:0045761; regulation of adenylate cyclase activity | 3.325E-06 | 1.010E-02 | ADRA2A, HRH3, TSHR |
| BP | GO:0009987; cellular process | GO:0007187; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger | 5.214E-06 | 1.135E-02 | ADRA2A, ADRA2C, HRH3, TSHR |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 1.168E-05 | 1.505E-02 | ADRA2A, ADRA2C |
| CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 2.749E-05 | 2.341E-02 | SMN1, SMN2 |
| CC | GO:0044464; cell part | GO:0005737; cytoplasm | 3.154E-05 | 2.439E-02 | ADRA2A, ADRA2C, CA2, CYP3A4, MAPK1, POLB, SMN1, SMN2, TDP1, TLR2 |
| CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 3.248E-05 | 2.439E-02 | SMN1, SMN2 |
| MF | Unclassified; | GO:0004871; signal transducer activity | 4.559E-05 | 3.101E-02 | ADRA2A, ADRA2C, HRH3, MAPK1, PPARA, TLR2, TSHR |
| CC | GO:0044464; cell part | GO:0043204; perikaryon | 5.629E-05 | 3.310E-02 | MAPK1, SMN1, SMN2 |
| MF | GO:0005488; binding | GO:0031690; adrenergic receptor binding | 6.359E-05 | 3.377E-02 | ADRA2A, ADRA2C |
| CC | GO:0044464; cell part | GO:0034719; SMN-Sm protein complex | 6.359E-05 | 3.377E-02 | SMN1, SMN2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 2.333E-05 | 2.800E-03 | HRH3, ADRA2C, ADRA2A, TSHR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 1.538E-04 | 9.227E-03 | MAPK1, ADRA2C, ADRA2A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 2.578E-04 | 1.031E-02 | MAPK1, PPARA, TSHR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 9.986E-04 | 2.397E-02 | MAPK1, TLR2 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 9.450E-04 | 2.397E-02 | CA2, CYP3A4 |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 2.089E-03 | 3.582E-02 | MAPK1, TLR2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 2.012E-03 | 3.582E-02 | MAPK1, TLR2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 2.580E-03 | 3.870E-02 | MAPK1, TLR2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 3.916E-03 | 4.699E-02 | MAPK1, TLR2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 3.263E-03 | 4.351E-02 | MAPK1, PPARA |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | HRH3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HRH3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; HRH3; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; HRH3; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Excessive daytime sleepiness | F51.1, G47.1 | HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C; HRH3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C; HRH3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obese insulin-resistant disorders | E11 | HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | HRH3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HRH3; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HRH3; |
| G00-G99: Diseases of the nervous system G00-G99 | Narcolepsy | G47.4 | HRH3; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2A; ADRA2C; HRH3; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | HRH3; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | HRH3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA2C; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; HRH3; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | HRH3; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HRH3; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
